**** Hiu qu c th khc nhau ty thuc vo c a, liu trnh v cch thc hin *** CNG DNG V LI CH S dng Glutathione thng xuyn gip: Lm trng da
Three risk alleles uncovered in genome-wide association studies on NASH patients include polymorphisms in the LD-associated genes HSD17B13 (114), PNPLA3 (115), and TM6SF2 (116)

According to British Society for Haematology (BSH) guidelines and NICE Clinical Knowledge Summaries (CKS), the primary beneficiaries include: Key patient groups who may require B12 injections include: Pernicious anaemia patients requiring lifelong hydroxocobalamin 1mg intramuscularly every 23 months following initial loading doses Patients with gastrointestinal disorders including those who have undergone gastrectomy or ileal resection, and patients with conditions affecting B12 absorption such as Crohn's disease or coeliac disease Strict vegans and vegetarians though oral supplementation is usually sufficient unless malabsorption is present Elderly patients who may have reduced gastric acid production affecting B12 absorption Patients taking certain medications including metformin (MHRA advises monitoring B12 levels in long-term users, particularly those with risk factors or symptoms), proton pump inhibitors, and H2-receptor antagonists long-term [6] Individuals with neurological symptoms such as paraesthesia, ataxia, or cognitive impairment related to B12 deficiency Pregnant women with confirmed deficiency (hydroxocobalamin for malabsorption

AOD9604 and Oral Bioavailability Research Pharmacokinetic profiling in pigs confirmed that AOD9604 is orally bioavailable, with intact peptide and its principal N-terminal truncation degradants (2aa and 3aa fragments) detected in plasma following oral dosing